continues to work with Congress, federal agencies, and other stakeholders to
ensure continued access to safe and effective hematologic drugs.
The FDA reported to ASH that the national shortage of tretinoin capsules (Vesanoid; all-trans retinoic acid [ATRA]) has been resolved. CHEPLAPHARM, Par Pharmaceutical, and Teva
Pharmaceutical have tretinoin capsules available for distribution. The shortage started in mid-February and was alarming to ASH members as it is a critical therapy for patients with acute promyelocytic leukemia (APL). ASH applauds the FDA for taking the important steps to mitigate the situation in a timely manner. ASH will continue to monitor the availability of the product and will alert members of any future supply issues. If you are still experiencing supply issues, please contact the FDA at email@example.com or by phone at 301-796-3400.